Fredrik C Kamme

US Patent:

7354742, Apr 8, 2008

Filed:

Feb 22, 2002

Appl. No.:

10/080795

Inventors:

Fredrik Kamme - San Diego CA, US
Jessica Y. Zhu - San Diego CA, US

Assignee:

Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ

International Classification:

C12P 19/34
C12Q 1/68

US Classification:

435 912, 435 6, 435 911

Abstract:

The present invention provides a new method for producing amplified RNA from a selected set of cells. This method combines and utilizes known methods in a novel way to produce the gene expression profiles. The methods of the present invention utilize thermostable DNA polymerases and RNase H to produce high fidelity second strand synthesis of nucleic acids from selected cells in a highly efficient mariner and in substantially reduced time.

US Patent:

20020156038, Oct 24, 2002

Filed:

Oct 4, 2001

Appl. No.:

09/971900

Inventors:

Pascal Bonaventure - San Diego CA, US
Hongqing Quo - San Diego CA, US
Xuejun Liu - San Diego CA, US
Fredrik Kamme - San Diego CA, US
Bernhard Meurers - La Jolla CA, US
Josepha Leysen - Oud-Turnhout, BE
Margot Bakker - Breda, NL

International Classification:

A61K048/00
C12Q001/68
C12M001/34

US Classification:

514/044000, 435/006000, 435/287200

Abstract:

Implementing gene expression to study drug action in the central nervous system is complicated by functional heterogeneity because of the existence of many different neuronal subtypes within the mammalian brain. The integration of laser capture microdissection (LCM) and RNA amplification with cDNA microarray technology allows for large-scale gene expression analysis at cellular level. Using this approach, we have generated gene expression profiles of imipramine, a reference antidepressant, and a new putative antidepressant, novelR1 in several laser-captured brain nuclei (locus coeruleus, dorsal raphe, hypothalamic paraventricular nucleus and hippocampus) of rats subjected to the chronic mild stress model (CMS) of depression.

US Patent:

20040259133, Dec 23, 2004

Filed:

Apr 15, 2004

Appl. No.:

10/826834

Inventors:

Fredrik Kamme - San Diego CA, US
Bernhard Meurers - San Diego CA, US
Dmitri Talantov - San Diego CA, US
Jingxue Yu - San Diego CA, US

International Classification:

C12Q001/68
G01N001/30
G01N033/48

US Classification:

435/006000, 435/040500

Abstract:

To preserve RNA in a biological sample for analysis, the sample is incubated with an RNA preservative capable of precipitating RNA in an aqueous solution, such as a triphenylmethane dye (e.g., methyl green, crystal violet, pararosaniline, or tris-(4-aminophenyl)methane), cresyl violet, or cobalt ions. RNA preservation may be used in an immunostaining assay and other histochemical methods.

US Patent:

20060105331, May 18, 2006

Filed:

May 30, 2003

Appl. No.:

10/514349

Inventors:

Fredrik Kamme - San Diego CA, US
Jessica Zhu - San Diego CA, US

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435006000, 435091200

Abstract:

Methods are described for eliminating single-stranded oligonucleotides from a sample prior to RNA transcription, thereby reducing non-template derived production of RNA. In one embodiment, a sample containing the template for RNA transcription is treated with one or more exonucleases to remove single-stranded oligonucleotides from the reaction mixture prior to RNA transcription. In another embodiment, the sample containing the template for RNA transcription is contacted with an oligonucleotide complementary to the single-stranded oligonucleotide present in the sample, and allowed to hybridize to form double-stranded oligonucleotides.

US Patent:

20060166258, Jul 27, 2006

Filed:

Mar 27, 2006

Appl. No.:

11/389923

Inventors:

Fredrik Kamme - San Diego CA, US
Bernhard Meurers - San Diego CA, US
Dmitri Talantov - San Diego CA, US
Jingxue Yu - San Diego CA, US

International Classification:

C12Q 1/68
G01N 1/30
G01N 33/48

US Classification:

435006000, 435040500

Abstract:

To preserve RNA in a biological sample for analysis, the sample is incubated with an RNA preservative capable of precipitating RNA in an aqueous solution, such as a triphenylmethane dye (e.g., methyl green, crystal violet, pararosaniline, or tris-(4-aminophenyl)methane), cresyl violet, or cobalt ions. RNA preservation may be used in an immunostaining assay and other histochemical methods.

US Patent:

20100179310, Jul 15, 2010

Filed:

Jan 8, 2010

Appl. No.:

12/684854

Inventors:

Fredrik Kamme - San Diego CA, US
Gary Bright - San Diego CA, US
Gustaf Angelborg - San Diego CA, US
James Linton - San Diego CA, US
Manfred Koller - San Diego CA, US

Assignee:

Cyntellect, Inc. - San Diego CA

International Classification:

C07H 21/00
C12Q 1/02
G01N 33/53
C12Q 1/68

US Classification:

536 2541, 435 29, 435 72, 435 6

Abstract:

Some aspects relate to methods for genetic analysis of selected cells from within a heterogeneous population of cells. The population of cells first can be partitioned. Selected cells are identified by imaging, and then specifically targeted and lysed by irradiation with an energy beam, resulting in specific release of their cellular contents into the culture medium. The culture medium then can be sampled and assayed for the desired nucleic acids.

US Patent:

20230025910, Jan 26, 2023

Filed:

Jun 17, 2022

Appl. No.:

17/842960

Inventors:

- Carlsbad CA, US
Fredrik Carl Kamme - Encinitas CA, US

Assignee:

Ionis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C12N 15/113
A61K 31/713

Abstract:

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or animal, and in certain instances reducing the amount of IFNAR1 protein in a cell or animal Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutières Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.